Nimvastid (Rivastigmine)

Rivastigmine, the active ingredient in Nimvastid, is an acetylcholinesterase inhibitor presented as an oral dosage form for oral use. It is indicated for the treatment of mild to moderate dementia associated with Alzheimer’s disease and Parkinson’s disease dementia in adult patients.

GNH USA supplies Nimvastid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from comprehensive regulatory support and timely delivery across multiple continents.

Rivastigmine is used in the management of dementia, targeting cholinergic deficits in neurodegenerative conditions.

Alzheimer’s disease dementia: improves cognitive function and daily living activities in patients with mild to moderate disease. Parkinson’s disease dementia: helps alleviate cognitive decline and supports overall mental performance in affected individuals.

Rivastigmine may be associated with several adverse reactions, ranging from mild to severe.

Common Side Effects: - Nausea - Vomiting - Diarrhea - Loss of appetite - Dizziness - Weight loss

Serious or Rare Side Effects: - Severe bradycardia - Gastrointestinal bleeding - Hepatic dysfunction - Acute cholinergic crisis - Stevens‑Johnson skin reaction - Seizures

When prescribing Rivastigmine, clinicians should consider several safety measures. - Dose titration: start with low dose and increase gradually as tolerated. - Renal impairment: monitor renal function and adjust therapy if needed. - Hepatic impairment: use with caution in patients with liver disease. - Cardiovascular disease: observe for bradycardia or syncope. - Concomitant anticholinergics: may reduce efficacy, review medication list. - Store at ambient temperature: keep in original container, protect from moisture and light.

Rivastigmine can interact with other medicines, requiring careful review.

Major Interactions (Avoid): - Other cholinesterase inhibitors (e.g., donepezil, galantamine): additive cholinergic effects. - Anticholinergic agents (e.g., atropine, antihistamines): may diminish therapeutic benefit. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase plasma levels.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may exacerbate bradycardia. - NSAIDs or anticoagulants: increased risk of gastrointestinal bleeding. - Serotonergic antidepressants: monitor for nausea and gastrointestinal upset.